TBE/iStock Editorial via Getty Images
A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NYSE:NVS) over alleged kickbacks involving its multiple sclerosis drug Gilenya can proceed.
The Second U.S. Circuit Court of Appeals in Manhattan ruled that whistleblower Steven Camburn can